Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australian bourse filing.
Four out of seven patients in the group have achieved a complete response following treatment with azer-cel, chemotherapy, as well as a low dose of interleukin 2, a protein that affects what happens between cells in the immune system, the filing added.
Azer-cel is a chimeric antigen receptor T-cell therapy, which targets CD19 to treat blood cancers.
Imugene said that it remains focused on continuing enrollment in the group, as well as evaluating the long-term durability of responses.
The firm's shares rose 8% in recent trading on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。